Empowering Ethiopia: Horizon Europe Grants €4M to Tackle Non-Communicable Diseases

By Staff Writer

August 17, 2023

The ENABLE research consortium has been awarded a generous €4 million grant from Horizon Europe to combat non-communicable diseases (NCDs) in Ethiopia.

The ENABLE consortium, a collaboration between the Norwegian Institute of Public Health (NIPH) and the Ethiopian Public Health Institute (EPHI), will kick off its mission in 2024 for a period of 4 years.

The project aims to establish a program, using evidence-based interventions, to promote healthy eating habits, increase physical activity, and reduce exposure to pollution within urban communities in Ethiopia.

This initiative will be delivered across four Ethiopian cities: Addis Ababa, Adama, Harar, and Jimma, targeting pregnant women and their children in particular.

This is a prime example of how combining public health, healthcare access, and environmental health, supported by digital tools, can significantly improve a population’s health.

This project aligns with Ethiopia’s National NCD prevention strategy and contributes to closing the global knowledge gap for implementing evidence-based interventions.

The team is led by Dr Eleni Papadopoulou (NIPH) and Dr Masresha Tessema (EPHI) as they embark on this vital mission.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.